Stay updated with breaking news from Biosimilar Product. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon.
Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities.
It's always good to have a villain, a "Snidely Whiplash" or other cartoon caricature to support an argument, especially if the issue is complex and fails the cocktail party test...